MAB Registration Exam common mistakes
MAB Registration Exam · Understand the traps and how to avoid them.
Treating the Medical Affairs role as identical to Sales or Marketing - for example, answering that an MSL's primary objective is to increase prescriptions or that Medical Affairs reports through the commercial organization.
Candidates with a commercial or sales background carry over familiar performance metrics and reporting lines, and the exam deliberately tests the functional separation of Medical Affairs from commercial functions.
What to do instead
Memorize the core mandate of Medical Affairs: scientific exchange, evidence generation, and patient safety, with independence from promotional targets. For any scenario question, ask 'who owns the science and the compliance boundary?' and route the activity to Medical Affairs, not Sales.
Confusing Phase I, II, III, and IV objectives - for instance, stating that Phase II establishes definitive efficacy and safety for approval, or that Phase III is primarily dose-finding.
The phases overlap in practice, and candidates rely on vague memory ('Phase II is the middle one') rather than precise endpoint logic, so they swap the primary purpose of adjacent phases.
What to do instead
Build a one-line anchor for each phase: I = safety/tolerability and PK in a small group; II = preliminary efficacy and dose-ranging; III = confirmatory efficacy and safety in a larger population for registration; IV = post-approval safety and real-world effectiveness. Test yourself by matching endpoints (MTD, ORR, OS, signal detection) to the correct phase.
Mixing up regulatory pathways and designations - using 'accelerated approval' and 'priority review' interchangeably, or applying orphan drug exclusivity rules to a standard approval.
The names sound similar and all relate to faster access, so candidates conflate the mechanism (surrogate endpoint plus confirmatory trial for accelerated approval) with the administrative timeline (priority review shortens review time).
What to do instead
Create a comparison table with columns for what the pathway changes (review clock vs. evidence standard vs. exclusivity period), the evidence required, and the post-approval obligation. Recall that accelerated approval requires confirmatory post-marketing studies and can be withdrawn if they fail.
Answering a Medical Information question by describing how to route the request to Sales or by promising off-label information without an unsolicited-request basis.
Candidates default to customer-service instincts ('keep the customer happy') and forget that Medical Information responses must be balanced, referenced, and handled within the unsolicited-request and fair-balance framework.
What to do instead
Apply a fixed checklist to every Med Info scenario: was the request unsolicited, is the response balanced and evidence-based, is it documented, and is it routed through Medical Information rather than commercial? Rehearse the standard-response and escalation pathways, including adverse event reporting triggers.
Describing MSL interactions as promotional detailing - for example, saying the MSL should 'drive adoption' or deliver sales messaging during a scientific exchange.
The MSL role overlaps with the field force in geography and stakeholder contact, so candidates blur the boundary and import promotional language into scientific exchange answers.
What to do instead
Frame every MSL activity around insight gathering, scientific exchange, and investigator support, and explicitly exclude product promotion. Practice rewriting promotional-sounding statements into compliant scientific-exchange statements, and identify which activities must be handed to commercial colleagues.
Treating a randomized controlled trial as sufficient evidence for all decisions, and failing to distinguish internal validity from external validity or to recognize the role of RWE in label expansions and payer dossiers.
Candidates learn RCT design first and over-apply it, missing the exam's emphasis on the totality of evidence, generalizability, and when real-world evidence is appropriate or insufficient.
What to do instead
For each evidence question, name the decision being supported (registration, label expansion, HTA submission, clinical guideline) and then judge whether RCT, observational, or RWE data fit. Note the key limitations of each design (confounding, selection bias, adherence measurement) and state them explicitly in your answer.
Failing to recognize a reportable adverse event in a scenario, or misclassifying seriousness versus severity - for example, calling a severe headache 'serious' or missing that a hospitalization makes a mild reaction serious.
Severity (intensity) and seriousness (patient/outcome impact) are easily conflated, and candidates overlook reporting timelines and the minimum criteria for a valid ICSR.
What to do instead
Memorize the seriousness criteria (death, life-threatening, hospitalization or prolongation, disability, congenital anomaly, medically important event) and separate them from severity grading. Then drill the four elements of a valid ICSR (identifiable patient, suspect product, reporter, event) and the expedited reporting clock for serious unexpected suspected adverse reactions.
Confusing cost-effectiveness analysis with budget impact analysis, or answering a market access question purely on clinical efficacy without addressing payer evidence requirements such as ICER, QALYs, or value dossiers.
Candidates from clinical backgrounds are comfortable with efficacy endpoints and unfamiliar with health-economic methods, so they substitute clinical arguments for economic ones.
What to do instead
Learn the distinction: cost-effectiveness compares efficiency per unit of health gain (ICER = incremental cost / incremental effect, often per QALY), while budget impact estimates total affordability for a population over time. Practice mapping a payer question to the correct analysis type and the correct dossier section.
Approving or describing an interaction that creates a conflict of interest - for example, arranging a gift, a lavish meal, or a consulting arrangement designed to influence prescribing - without recognizing the compliance problem.
Candidates judge interactions by whether they 'feel normal' in their local market rather than by the applicable code and policy, and local norms often exceed what the rules permit.
What to do instead
Apply the tests explicitly: does the interaction have a legitimate scientific or educational purpose, is it proportionate and transparent, and would it withstand public and regulatory scrutiny? Recall that transfers of value must be documented and disclosed, and that consulting arrangements require a genuine need, fair market value, and written agreements.
Describing publication planning as marketing-driven - for example, agreeing that a sponsor may suppress a negative trial, ghostwrite manuscripts, or select authors to control messaging.
Candidates conflate publication strategy with promotional strategy and underestimate the ethical and regulatory obligations around disclosure, authorship, and trial registration.
What to do instead
Anchor on the principles: results must be published regardless of outcome, authorship requires substantive contribution per ICMJE criteria, professional medical writers must be disclosed, and trials must be registered with results posted. For any publication scenario, ask whether the proposed action would survive disclosure and whether it respects the independence of the authors.